title: [Signification of liver metastases of colorectal cancer with special reference to recurrence in the residual liver after hepatic resection].
abstract: In the patients with liver metastases of colorectal cancer, pre-and post operative intra-arterial infusion chemotherapy was evaluated for prevention of recurrence in the residual liver after hepatic resection. Materials are sixty-five hepatectomized patients from May 1981 to 1992. Therapies were subdivided into five groups. I: pre-and postoperative non-therapy (n = 3); II: postoperative chemotherapy (n = 22); III: postoperative intra-arterial infusion chemotherapy (n = 12); IV: pre-operative intra-arterial infusion chemotherapy + postoperative chemotherapy (n = 15); and V: pre-and postoperative intra-arterial infusion chemotherapy (n = 13). In recurrence rate in the residual liver, I to IV groups showed as high as 50-100%. However, the disease-free survival rate was 100% in V group, revealing a significant difference between the other four groups. Accordingly, in order to prevent recurrence in the residual liver of hepatectomized patients with liver metastases of colorectal cancer and prolong the disease-free interval, we consider that pre-and post-operative intra-arterial infusion chemotherapy can be effective, compared to pre-or postoperative intra-arterial infusion chemotherapy alone.
authors.affiliation: Dept. of Surgery II, School of Medicine, Chiba University.
authors.forename: K
authors.initials: K
authors.lastname: Okuyama
authors.forename: T
authors.initials: T
authors.lastname: Awano
authors.forename: N
authors.initials: N
authors.lastname: Tohnosu
authors.forename: Y
authors.initials: Y
authors.lastname: Koide
authors.forename: H
authors.initials: H
authors.lastname: Matsubara
authors.forename: H
authors.initials: H
authors.lastname: Nakaichi
authors.forename: Y
authors.initials: Y
authors.lastname: Funami
authors.forename: K
authors.initials: K
authors.lastname: Matsushita
authors.forename: H
authors.initials: H
authors.lastname: Amano
authors.forename: T
authors.initials: T
authors.lastname: Ochiai
mesh_terms: D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D015179:Colorectal Neoplasms / Q000473:pathology*; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006498:Hepatectomy; D006801:Humans; D015918:Infusion Pumps, Implantable; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary / Q000601:surgery; D016685:Mitomycin / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000517:prevention & control
chemical_list: D016685:Mitomycin; D004317:Doxorubicin; C017367:carmofur; D005472:Fluorouracil